Quality of Life After Kidney Transplantation: A Prospective Study

Kostro, Justyna; Hellmann, Andrzej; Kobiela, Jarosław; Skóra, Iwona; Lichodziejewska‐Niemierko, Monika; Dębska-Ślizień, Alicja; Śledziński, Zbigniew

doi:10.1016/j.transproceed.2015.10.058

Cited by 94 publications

(80 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1. Compared to US dialysis patients [13], Poland dialysis patients [14], and Singapore dialysis patients [15], our data showed a poor score only in sexual function. The different rate of QOL in hemodialysis patients influenced by some factors such as race [16], change in kidney function [17], stage of anemia [11], etc.…”

Section: Discussioncontrasting

confidence: 54%

Quality of Life of Chronic Kidney Disease Patients With Routine Hemodialysis in General Hospitals in Sleman Yogyakarta

Hakim

Andayani

Irijanto

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: To elicit quality of life (QOL) of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin, to compare the QOL of CKD patients with routine hemodialysis receiving different erythropoietin, and to explore the change in QOL over six months for patients managed in the hospitals. Methods:A multicenter prospective study was conducted among adult CKD patients in Yogyakarta. QOL was measured using kidney disease quality of life-short form (KDQOL-SF TM ) questionnaire and a FACIT fatigue scale questionnaire. CKD patients were divided into 2 groups: those receiving erythropoietin alpha (n=74) and those receiving erythropoietin beta (n=39). Both groups were asked to complete the KDQOL-SF TM Results: In the first period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 77.24: 80.21 and 3.35: 3.49 while in the second period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 80.45: 83.95 and 3.45: 3.56. questionnaire and a FACIT fatigue scale questionnaire two times in six months range. Conclusion:Erythropoietin can improve QOL of CKD patients with routine hemodialysis, while erythropoietin beta gives more improvement, but statistically, it doesn't different significantly.

show abstract

Section: Discussioncontrasting

confidence: 54%

Quality of Life of Chronic Kidney Disease Patients With Routine Hemodialysis in General Hospitals in Sleman Yogyakarta

Hakim

Andayani

Irijanto

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…The SF‐36 domains that have been reported to show most improvement post‐transplantation are role‐physical, vitality and general health . In the current study, apart from work status, comparison of baseline and post‐transplant HRQoL scores indicated significant improvements in all domains, which is consistent with most longitudinal studies summarized in Table S1, Supporting Information and studies of questionable validity, that included assessment of pre‐ and post‐transplant HRQoL by recall, more than 12 months after transplantation, and up to 10 years after transplantation . However, not all studies show improvement.…”

Section: Discussionmentioning

confidence: 99%

Health‐related quality of life following kidney and simultaneous pancreas kidney transplantation

et al. 2019

View full text Add to dashboard Cite

Introduction Kidney and simultaneous pancreas kidney (SPK) transplant recipients are younger and fitter than most other dialysis patients, but are also more vulnerable in areas of social, emotional and physical interaction. Few studies have tracked their post‐transplant health‐related quality of life (HRQoL). Aim To assess HRQoL following kidney and SPK transplantation, with comparison to dialysis patients, people with multiple co‐morbidities and general population data. Methods Patients completed the Kidney Disease Quality of Life Short Form (KDQOL‐SF™) 1.3 to assess their pre‐transplant HRQoL within 4 weeks of transplantation and 12 months later. Demographic and laboratory data were collected on participating patients and on non‐participating patients at both time‐points. Results Of 118 patients who completed the baseline KDQOL‐SF™, 75 (57 kidney and 18 SPK) completed the 1 year survey. Compared to baseline, 12 months HRQoL scores improved in all domains except for work status, exceeded those of patients on dialysis and, except for emotional wellbeing and mental health, exceeded the scores of people with multiple co‐morbidities. For female transplant recipients, 12 months HRQoL scores were not statistically different from similarly aged women in the general population. Male transplant recipients had similar scores for bodily pain and energy/fatigue, but lower scores in other domains. Compared to kidney‐only transplant recipients, SPK recipients achieved higher scores in work and sleep domains. Conclusion Improvements in most HRQoL domains occur within 1 year of kidney or SPK transplantation, and women achieve similar HRQoL to women in the general population. These data are encouraging for patients contemplating transplant listing.

show abstract

“…In addition to superior patient survival compared to remaining on the waiting list, kidney transplantation is pursued due to the improvement in quality of life (QOL) that it confers[32,33]. Transplant patients have superior QOL compared to dialysis patients[34], though this may not be a fair comparison given that transplanted patients are a highly selected group.…”

Section: What Outcomes Can Be Expected Post-transplant?mentioning

confidence: 99%

Older candidates for kidney transplantation: Who to refer and what to expect?

Concepcion¹,

Forbes²,

Schaefer³

2016

WJT

View full text Add to dashboard Cite

The number of older end-stage renal disease patients being referred for kidney transplantation continues to increase. This rise is occurring alongside the continually increasing prevalence of older end-stage renal disease patients. Although older kidney transplant recipients have decreased patient and graft survival compared to younger patients, transplantation in this patient population is pursued due to the survival advantage that it confers over remaining on the deceased donor waiting list. The upper limit of age and the extent of comorbidity and frailty at which transplantation ceases to be advantageous is not known. Transplant physicians are therefore faced with the challenge of determining who among older patients are appropriate candidates for kidney transplantation. This is usually achieved by means of an organ systems-based medical evaluation with particular focus given to cardiovascular health. More recently, global measures of health such as functional status and frailty are increasingly being recognized as potential tools in risk stratifying kidney transplant candidates. For those candidates who are deemed eligible, living donor transplantation should be pursued. This may mean accepting a kidney from an older living donor. In the absence of any living donor, the choice to accept lesser quality kidneys should be made while taking into account the organ shortage and expected waiting times on the deceased donor list. Appropriate counseling of patients should be a cornerstone in the evaluation process and includes a discussion regarding expected outcomes, expected waiting times in the setting of the new Kidney Allocation System, benefits of living donor transplantation and the acceptance of lesser quality kidneys.

show abstract

Quality of Life After Kidney Transplantation: A Prospective Study

Cited by 94 publications

References 16 publications

Quality of Life of Chronic Kidney Disease Patients With Routine Hemodialysis in General Hospitals in Sleman Yogyakarta

Quality of Life of Chronic Kidney Disease Patients With Routine Hemodialysis in General Hospitals in Sleman Yogyakarta

Health‐related quality of life following kidney and simultaneous pancreas kidney transplantation

Older candidates for kidney transplantation: Who to refer and what to expect?

Contact Info

Product

Resources

About